AbbVie Announces Positive Results of Study Evaluating SKYRIZI in Plaque Psoriasis Patients AbbVie announced new 52-week data from an open-label, a single-arm study demonstrating improved plaque pso...
Burn is one of the most severe and rapidly growing burdens worldwide, leading to a very high number of mortality and morbidity yearly. It can have intense physical, socioeconomic, and psychological consequences on the person and their family. As per the latest assessment by DelveInsight, incident cases of burns req...
Find More
Leo Pharma Announces Positive Results of Phase III Hand Eczema Clinical Trial LEO Pharma A/S, a global leader in medical dermatology, announced that the DELTA 2 trial yielded positive results. DELTA 2 is the second of two pivotal phase III clinical trials involving delgocitinib cream, an investigational topical ...
Find More
Androgenetic alopecia is a genetic disorder caused by an overreaction to androgens. This condition affects up to 50% of males and females and is characterized by progressive loss of terminal hair on the scalp at any time after puberty. As per Asadi (2020), androgenetic alopecia is the common cause of hair loss in m...
Find More
The idea of aesthetic implants or cosmetic surgery has always been a topic of conversation and debate in the healthcare market. Despite that, the demand for aesthetic implants has grown several folds over the past few years, especially among the younger generation, to enhance their physical appearance and to look m...
Find More
Amgen Inc. Agrees to Purchase Dublin-based Horizon Therapeutics Plc. for €24.7 Billion Amgen Inc. has agreed to buy Dublin-based Horizon Therapeutics Plc. for €24.7 billion ($26 billion), in a deal that could face further delays or a breakdown in negotiations. Following Sanofi's withdrawal from the race, c...
Find More
OR3O™ Dual Mobility System launched by Smith+Nephew in Japan for use in primary and revision hip arthroplasty On September 20, 2022, Smith+Nephew, a leading global portfolio medical technology business, announced the launch of OR3O Dual Mobility System for use in primary and revision hip arthro...
Find More
Amgen Reveals the Top-line Result of its CodeBreak-200 trial of Lumakras in Lung Cancer The top-line result of Amgen's CodeBreak-200 trial of Lumakras in lung cancer was presented in abstract form at ESMO two weeks ago, showing a 34% improvement in progression-free survival (PFS) compared to chemotherapy. The fu...
Find More
Currently, there is no cure and no FDA-approved treatments for alopecia. Thus, the alopecia areata treatment market is completely dominated by off-label drug therapies. Depending on the extent of hair loss and age, there are a variety of alopecia areata treatment options are available. The main goal of treatment is...
Find More
FDA Approves AstraZeneca’s Imfinzi for Biliary Tract Cancer Imfinzi, a checkpoint inhibitor developed by AstraZeneca, has been approved by the FDA as the first immunotherapy for biliary tract cancer (BTC), a rare and aggressive form of cancer with few treatment options. Imfinzi (durvalumab) has been approved by ...
Find More
Myocardial infarction (MI), colloquially known as “heart attack” is caused by decreased or compl.....
Find More
Acute ischemic stroke (AIS) is a medical emergency caused by decreased blood flow to the brain, whic.....
Find More
Rheumatoid Arthritis (RA) is a chronic, inflammatory autoimmune disease that leads to progressive an.....
Find More-Agonist.png "Toll-like Receptors Agonist")
The American Society of Clinical Oncology is a platform that provides a global connection to researchers, pharma companies, and healthcare professions standing against cancer, finding a cure for it.
